Results for this period
First quarter1 June 2026 to 31 August 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Although the revision to dispensing fees was a factor reducing revenue, net sales increased as dispensing revenue rose with the expansion in the number of stores resulting from M&A in the previous consolidated fiscal year. In terms of profitability, the cost of sales ratio rose due to the revision to dispensing fees, changes in procurement conditions resulting from the revision to drug prices, and longer prescription periods, resulting in declines in operating profit and ordinary profit.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 June 2026 to 31 August 2026 |
| Net Sales | ¥17,242 million (YoY +2.9%) |
| Operating profit | ¥68 million (YoY -54.8%) |
| Ordinary income | ¥79 million (YoY -31.3%) |
| Profit attributable to owners of the parent | ¥-36 million |
| Net income per share | (¥3.20) |
| Equity ratio | End of the current fiscal period 20.6 / End of previous period 20.3 |
| Total assets | ¥31,221 million |
| Net assets | ¥6,657 million |
| Full-year earnings forecast | Net Sales ¥70,604 million (YoY +1.6%) / Operating profit ¥1,014 million (YoY +3.5%) / Ordinary income ¥736 million (YoY +2.9%) / Net income ¥11 million (YoY -90.0%) |
| Annual Dividend Forecast | ¥14 → ¥14（0.0%） |
| Segment revenue | Dispensing Pharmacy Business ¥14,474 million, Retail Business ¥2,060 million, Medical Records Storage and Management Business ¥138 million, Medical mall management business ¥123 million, Other ¥445 million |
| Segment profit | Dispensing Pharmacy Business ¥158 million, Retail Business ¥-33 million, Medical Records Storage and Management Business ¥4 million, Medical mall management business ¥18 million, Other ¥5 million |
| Depreciation and amortization | ¥184 million |
| Impairment loss | No applicable matters. |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥0 million, Subsidy Income ¥11 million / Extraordinary loss Loss on sale of fixed assets ¥1 million, Loss on Disposal of Fixed Assets ¥0 million, Loss on reduction of fixed assets ¥11 million |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New — companies / Excluded — companies / Company name No |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Analysts and institutional investors |
| Issued Shares at Period-End | 12,060,381 shares |
| Treasury Shares at Period-End | 557,856 shares |
| Factors Behind Changes in Business Performance | Although the revision to dispensing fees was a factor reducing revenue, net sales increased as dispensing revenue rose with the expansion in the number of stores resulting from M&A in the previous consolidated fiscal year. In terms of profitability, the cost of sales ratio rose due to the revision to dispensing fees, changes in procurement conditions resulting from the revision to drug prices, and longer prescription periods, resulting in declines in operating profit and ordinary profit. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Although the revision to dispensing fees was a factor reducing revenue, net sales increased as dispensing revenue rose with the expansion in the number of stores resulting from M&A in the previous consolidated fiscal year. In terms of profitability, the cost of sales ratio rose due to the revision to dispensing fees, changes in procurement conditions resulting from the revision to drug prices, and longer prescription periods.